-
1.发明授权Glycopeptide antibiotics Bu-2231 A and B and process for producing same 失效GLYCOPEPTIDE抗生素BU-2231A和B及其生产方法
公开(公告)号：US4051237A
公开(公告)日：1977-09-27
申请号：US608494
申请日：1975-08-28
IPC分类号： C12P1/06 , A01N63/02 , A61K35/74 , A61P31/04 , C07G11/00 , C07K9/00 , C12P1/04 , C12P21/00 , C12R1/465 , F16J15/38
CPC分类号： C07K9/003 , Y10S435/803 , Y10S435/822 , Y10S435/886 , Y10S435/891
摘要： A novel water-soluble basic glycopeptide antibiotic complex designated herein as Bu-2231 is produced by fermentation of a Bu-2231-producing strain of Streptoalloteichus hindustanus. Complex Bu-2231 and two of its major components designated herein as Bu-2231 A and B are found to inhibit the growth of various Gram-positive and Gram-negative and acid-fast bacteria as well as certain plant pathogens. The complex and components Bu-2231 A and B are also useful in inhibiting the growth of various tumors in rodents, for example, Walker 256 carcinosarcoma and Lewis Lung carcinoma.
-
2.发明授权Fermentation process for producing apramycin and nebramycin factor V' 失效生产APRAMYCIN和NEBRAMYCIN因子V'TOMITA的发酵方法; KOJI
公开(公告)号：US4032404A
公开(公告)日：1977-06-28
申请号：US705210
申请日：1976-07-14
申请人： Koji Tomita , Hiroshi Tsukiura , Hiroshi Kawaguchi
发明人： Koji Tomita , Hiroshi Tsukiura , Hiroshi Kawaguchi
CPC分类号： C07H15/234 , Y10S435/822
摘要： A fermentation process is disclosed for preparing the known aminoglycoside antibiotics apramycin and nebramycin factor V' by culturing Streptoalloteichus hindustanus A.T.C.C. 31217, 31218 or 31219. The so-produced nebramycin factor V' may subsequently be converted to tobramycin by base catalyzed hydrolysis.
-
公开(公告)号：US4108725A
公开(公告)日：1978-08-22
申请号：US714202
申请日：1976-08-13
IPC分类号： C12P19/44 , A61K31/70 , A61K31/7028 , A61P31/04 , C07H15/04 , C12P1/04 , C12R1/38 , C12D9/20
CPC分类号： C07H15/04 , Y10S435/874
摘要： A novel aminoglycoside antibiotic complex designated herein as Bu-2183 is produced by fermentation of Pseudomonas sp. strain D946-B83, A.T.C.C. 31086. Complex Bu-2183 is known to consist of at least five components, said components being herein designated Bu-2183 A, A.sub.2, B, C and D. The complex and the individual aminoglycoside components Bu-2183 A, A.sub.2, and B are found to have a broad spectrum of antibacterial activity and are especially useful in inhibiting aminoglycoside-resistant organisms including Pseudomonas species.
摘要翻译： 本文命名为Bu-2183的新型氨基糖苷类抗生素复合物是通过发酵假单胞菌属（Pseudomonas sp。 菌株D946-B83，A.T.C.C. 已知复合物Bu-2183由至少五种组分组成，所述组分在本文中称为Bu-2183A，A2，B，C和D.复合物和单独的氨基糖苷组分Bu-2183A，A2和B 被发现具有广谱的抗菌活性，并且特别可用于抑制氨基糖苷类抗性生物体，包括假单胞菌属物种。
-
公开(公告)号：US4169096A
公开(公告)日：1979-09-25
申请号：US841242
申请日：1977-10-11
申请人： Hiroshi Kawaguchi , Hiroshi Tsukiura , Koji Tomita
发明人： Hiroshi Kawaguchi , Hiroshi Tsukiura , Koji Tomita
IPC分类号： C07D493/18 , A61K31/40 , A61P31/04 , C07D493/20 , C12P17/18 , C12R1/29 , C07D207/12
CPC分类号： C07D493/20 , C12P17/181
摘要： A novel antibiotic complex designated herein as Bu-2313 is produced by fermentation of Micropolyspora sp. A.T.C.C. 31295, 31296, 31297 and 31298. The complex is separated into two bioactive components, Bu-2313A and BU-2313B, which are structurally related to the streptolydigin-tirandamycin group of antibiotics. They are active against anaerobic bacteria.
摘要翻译： 本文称为Bu-2313的新型抗生素复合物是通过微孢子虫发酵产生的。 A.T.C.C. 31295,31296,31297和31298。将复合物分成两种生物活性成分Bu-2313A和BU-2313B，其结构上与抗生素的链霉抗生物素霉素组相关。 它们对厌氧菌有活性。
-
公开(公告)号：US4012576A
公开(公告)日：1977-03-15
申请号：US627391
申请日：1975-10-30
IPC分类号： A61K31/70 , A61K31/7028 , A61P31/04 , C07H15/04 , C12P1/04 , C12P19/44 , A61K35/00 , C07H15/22
CPC分类号： C07H15/04 , Y10S435/874
摘要： A novel aminoglycoside antibiotic complex designated herein as Bu-2183 is produced by fermentation of Pseudomonas sp. strain D946-B83, A.T.C.C. 31086. Complex Bu-2183 is known to consist of at least five components, said components being herein designated Bu-2183 A, A.sub.2, B, C and D. The complex and the individual aminoglycoside components Bu-2183 A, A.sub.2, and B are found to have a broad spectrum of antibacterial activity and are especially useful in inhibiting aminoglycoside-resistant organisms including Pseudomonas species.
摘要翻译： 本文命名为Bu-2183的新型氨基糖苷类抗生素复合物是通过发酵假单胞菌属（Pseudomonas sp。 菌株D946-B83，A.T.C.C. 已知复合物Bu-2183由至少五种组分组成，所述组分在本文中称为Bu-2183A，A2，B，C和D.复合物和单独的氨基糖苷组分Bu-2183A，A2和B 被发现具有广谱的抗菌活性，并且特别可用于抑制氨基糖苷类抗性生物体，包括假单胞菌属物种。
-
6.发明授权Antibiotics produced by fermentation of a novel strain of Streptomyces hygroscopicus 失效通过发酵吸水链霉菌+ B链霉菌菌株产生的抗生素
公开(公告)号：US4504580A
公开(公告)日：1985-03-12
申请号：US507194
申请日：1983-06-23
CPC分类号： C12R1/55 , C07H15/232 , C12P19/46 , C12P19/50 , C12P19/52 , Y10S435/898
摘要： Antibiotic Bu-2659 complex, containing components A, B, C, D and E, is produced by cultivation of Streptomyces hygroscopicus Strain No. J296-21, ATCC No. 39150.
摘要翻译： 含有组分A，B，C，D和E的抗生素Bu-2659复合物是通过培养吸水链霉菌菌株菌株J296-21，ATCC 39150得到的。
-
7.发明授权1-Deamino-1-hydroxy-aminoglycoside compounds, antibacterial compositions and method of use 失效1-脱氨基-1-羟基 - 氨基糖苷类化合物，抗菌组合物及使用方法
公开(公告)号：US4468386A
公开(公告)日：1984-08-28
申请号：US409740
申请日：1982-08-19
IPC分类号： A61K31/70 , A61K31/7028 , A61K31/7034 , A61K31/7036 , A61P31/04 , C07H15/224 , C07H15/23 , C07H15/232 , C12P19/46 , C12P19/50 , C12P19/52 , C12R1/465 , A61K31/71 , C07H15/22
CPC分类号： C12R1/55 , C07H15/232 , C12P19/46 , C12P19/50 , C12P19/52
摘要： Antibiotic Bu-2659 complex, containing components A, B, C, D and E, is produced by cultivation of Streptomyces hygroscopicus Strain No. J296-21, ATCC No. 39150.
摘要翻译： 含有组分A，B，C，D和E的抗生素Bu-2659复合物是通过培养吸水链霉菌菌株菌株J296-21，ATCC 39150得到的。
-
公开(公告)号：US4320199A
公开(公告)日：1982-03-16
申请号：US203778
申请日：1980-11-03
申请人： Koji Tomita , Hiroshi Tsukiura , Hiroshi Kawaguchi
发明人： Koji Tomita , Hiroshi Tsukiura , Hiroshi Kawaguchi
CPC分类号： C12R1/01 , C12P17/10 , Y10S435/822
摘要： The known antibiotic, nocardicin, is produced by submerged aerobic cultivation of Microtetraspora caesia sp. nov. ATCC 31724 or 31725.
摘要翻译： 已知的抗生素，诺卡氏菌素，是通过潜在的有氧培养的Microtetraspora caesia sp。 nov。 ATCC 31724或31725。
-
9.发明授权Production of antibiotics by fermentation of novel strains of Micropolyspora caesia 失效通过发酵微孢子虫的新菌株生产抗生素
公开(公告)号：US4181574A
公开(公告)日：1980-01-01
申请号：US960200
申请日：1978-11-13
申请人： Hiroshi Kawaguchi , Hiroshi Tsukiura , Koji Tomita
发明人： Hiroshi Kawaguchi , Hiroshi Tsukiura , Koji Tomita
IPC分类号： C07D493/20 , C12P17/18 , C12D9/14
CPC分类号： C07D493/20 , C12P17/181 , C12R1/01 , C12R1/29 , Y10S435/822
摘要： A novel antibiotic complex designated herein as Bu-2313 is produced by fermentation of Micropolyspora sp. A.T.C.C. 31295, 31296, 31297 and 31298. The complex is separated into two bioactive components, Bu-2313A and Bu-2313B, which are structurally related to the streptolydigin-tirandamycin group of antibiotics. They are active against anaerobic bacteria.
摘要翻译： 本文称为Bu-2313的新型抗生素复合物是通过微孢子虫发酵产生的。 A.T.C.C. 31295,31296,31297和31298。该复合物被分成两种生物活性组分Bu-2313A和Bu-2313B，其结构上与抗生素的链霉素 - 蒂拉达霉素组相关。 它们对厌氧菌有活性。
-
公开(公告)号：US4409210A
公开(公告)日：1983-10-11
申请号：US339355
申请日：1982-01-15
IPC分类号： C12N1/20 , A23K20/195 , A61K35/74 , A61K38/00 , A61P17/00 , A61P31/04 , C07K5/117 , C07K7/06 , C07K11/02 , C07K14/195 , C07K14/41 , C12P21/02 , C12P21/04 , C12R1/01 , A61K37/00 , C07C103/52
CPC分类号： C12R1/01 , C07K5/1024 , C07K7/06 , A61K38/00 , Y10S930/19 , Y10S930/27
摘要： A novel water-soluble peptide designated herein as Bu-2517 is produced by fermentation of Empedobacter sp. strain G393-B445 (ATCC 31962). The antibiotic exists in a cyclic depsipeptide structure and contains the amino acids D-serine, D-proline, L-proline, D-threo-.beta.-hydroxyaspartic acid, L-threo-.beta.-hydroxyaspartic acid, L-arginine and trans-L-3-hydroxyproline and the residue of the C.sub.14 fatty acid, 3-hydroxytetradecanoic acid. The Bu-2517 antibiotic inhibits the growth of a variety of aerobic and anaerobic gram-positive bacteria.
摘要翻译： 本文命名为Bu-2517的新型水溶性肽是通过Empedobacter sp。 菌株G393-B445（ATCC 31962）。 抗生素存在于环状肽末端结构中，含有D-丝氨酸，D-脯氨酸，L-脯氨酸，D-苏氨酸-β-羟基天冬氨酸，L-苏氨酸-β-羟基天冬氨酸，L-精氨酸和反式-L-氨基酸 3-羟基脯氨酸和C14脂肪酸的残基，3-羟基十四烷酸。 Bu-2517抗生素抑制各种需氧和厌氧革兰氏阳性菌的生长。
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.021 秒)
